Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta in gemcitabine-refractory pancreatic cancer
NCT00864513Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Oct 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemetrexed in pancreatic cancer (PC), sponsored by Georgetown University. Primary endpoint: Progression-Free Survival at 6 months. Started Oct 2007; status: terminated.
02
Drugs
pemetrexed
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00864513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00864513.